XON - Intrexon Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.95
-0.52 (-3.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.47
Open14.27
Bid13.62 x 4000
Ask13.94 x 3000
Day's Range13.39 - 14.79
52 Week Range10.26 - 20.16
Volume2,097,371
Avg. Volume1,352,409
Market Cap1.911B
Beta (3Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)-1.43
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.75
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    Oxitec to Develop 2nd Friendly™ Mosquito Strain Designed to Combat Malaria-Spreading Mosquitoes

    OXFORD, England , October 18, 2018 /PRNewswire/ -- E xpanded collaboration with the Bill & Melinda Gates Foundation will leverage Oxitec ' s Friendly™ biological engineering platform to develop a self-limiting ...

  • PR Newswire3 days ago

    Oxitec to Develop 2nd Friendly™ Mosquito Strain Designed to Combat Malaria-Spreading Mosquitoes

    OXFORD, England , October 18, 2018 /PRNewswire/ -- E xpanded collaboration with the Bill & Melinda Gates Foundation will leverage Oxitec ' s Friendly™ biological engineering platform to develop a self-limiting ...

  • GlobeNewswire4 days ago

    AquaBounty receives construction loan to support development efforts at its Rollo Bay property

    AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), announces that the Company’s Canadian subsidiary has received a construction loan in the amount of CA$2.0 million (US$1.6 million) from the Department of Economic Development of the Province of Prince Edward Island.  The proceeds of the loan will be used to complete construction of the Company’s 250-metric ton production facility on its Rollo Bay site. The Rollo Bay site, which includes an R&D hatchery, is currently undergoing construction of a 250-metric ton production facility and a broodstock facility.  Once complete, 20-30 technical jobs are expected to be added to AquaBounty’s operation.

  • GlobeNewswire4 days ago

    INVESTIGATION UPDATE for XON, APOG and ATASY: Levi & Korsinsky, LLP Reminds Investors of Investigations on Behalf of Shareholders

    NEW YORK, Oct. 16, 2018 -- Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies..

  • GlobeNewswire8 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation (“Intrexon” or the “Company”) (NASDAQ: XON).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On this news, Intrexon’s share price fell $0.34 per share, or 2.21%, to close at $15.05 per share on August 10, 2018.  Then, on August 13, 2018, Intrexon filed an amended and restated 10-Q for the quarter ended March 31, 2018.  On this news, Intrexon’s share price fell $0.95 per share, or 6.31%, to close at $14.10 per share on August 13, 2018.

  • GlobeNewswire12 days ago

    Ziopharm and Precigen Redefine Relationships, Announce New License Agreement

    Ziopharm to Host Conference Call at 8 a.m. Through the new agreement, Ziopharm will primarily focus its resources on developing its Controlled IL-12 and Sleeping Beauty (SB) T-cell receptor (TCR) platform technologies which have the capability to treat solid tumors, while Intrexon further establishes Precigen as a therapeutics company concentrating on immuno-oncology, autoimmune and infectious disease therapies. With this exclusive license, Ziopharm now has full developmental control and exclusivity utilizing SB for TCRs targeted towards neoantigens and public antigens.

  • ACCESSWIRE17 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    NEW YORK, NY / ACCESSWIRE / October 3, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (XON). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Intrexon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • ACCESSWIRE24 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    NEW YORK, NY / ACCESSWIRE / September 26, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (XON). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether Intrexon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Intrexon’s Latest Pitch: We’re a Pot Stock
    Motley Fool25 days ago

    Intrexon’s Latest Pitch: We’re a Pot Stock

    Intrexon wants to make it easier for companies to create products that are high in cannabinoids.

  • Implied Volatility Surging for Intrexon (XON) Stock Options
    Zacks25 days ago

    Implied Volatility Surging for Intrexon (XON) Stock Options

    Investors need to pay close attention to Intrexon (XON) stock based on the movements in the options market lately.

  • ACCESSWIRE26 days ago

    Today’s Research Reports on Stocks to Watch: Intrexon and Tilray

    NEW YORK, NY / ACCESSWIRE / September 25, 2018 / While one marijuana stock saw big gains on Monday another one came crashing down. Tilray saw big losses again on Monday despite a positive announcement. ...

  • GlobeNewswire26 days ago

    Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

    Ziopharm Oncology, Inc. (ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York on Tuesday, Oct. 2, at 2:15 p.m. ET. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.

  • ACCESSWIRE26 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    NEW YORK, NY / ACCESSWIRE / September 24, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (XON). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether Intrexon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Zacks26 days ago

    Merger Mania: Examining the Latest M&A News & Trends | Free Lunch

    Ryan McQueeney breaks down the latest merger & acquisition news involving Comcast and Sky, Pandora and Sirius XM, and Barrick Gold and Randgold Resources. He also highlights an interesting new marijuana play from biotech DNA expert Intrexon. Later, he discusses recent M&A trends and data.

  • Intrexon, Once a Fighter of Zika, Pivots to Join Pot Mania
    Bloomberg26 days ago

    Intrexon, Once a Fighter of Zika, Pivots to Join Pot Mania

    Engineering mosquitoes and salmon didn’t capture investors’ imagination for Intrexon Corp. So now it’s looking to join the marijuana frontier. The biotech firm run by Chief Executive Officer and Chairman Randal Kirk surged as much as 38 percent intraday, the biggest jump in more than five years, after saying the company had engineered a yeast strain to extract “low-cost, robust and consistent” cannabinoids via a fermentation process for medical use. Before today, shares had shed more than 68 percent of their value since Sept. 2015 as Intrexon’s forays into genetic engineering including tweaking salmon -- dubbed Frankenfish by detractors -- and mosquitoes to combat the spread of the Zika virus failed to curry favor with investors.

  • Why Intrexon Corporation Is Skyrocketing Today
    Motley Fool26 days ago

    Why Intrexon Corporation Is Skyrocketing Today

    Intrexon's potential entry into the cannabis industry generated enthusiasm among investors.

  • PR Newswire27 days ago

    Intrexon Announces Advances in Production of Medical Cannabis

    BUDAPEST, Hungary, Sept. 24, 2018 /PRNewswire/ -- Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced advances in the development of its microbial platform to produce cannabinoids for medical uses.  Through Intrexon's proprietary technologies, the Company has engineered a yeast strain to produce low-cost, robust and consistent cannabinoid outputs via fermentation.  This process utilizing microbes has potential to provide greater supply-chain security, and avoids the resource-intensive isolation that often leads to quality and quantity variability in end products. Further, this versatile strain was designed to enable the production of cannabinoids that only are produced today in miniscule amounts in cannabis plants as well as novel cannabinoids.  The Company has scaled the process and achieved titers approaching commercially relevant targets with anticipated production of pure cannabinoids at COGS $1,000/kg.

  • ACCESSWIRElast month

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (NYSE: XON). Such ...

  • Barrons.comlast month

    How to Make a Killing in Gene Therapy

    Legendary short-seller Tom Barton now focuses on early-stage biotech investments. He shares his secrets.

  • PR Newswirelast month

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intrexon Corporation (XON)

    NEW YORK , Sept. 17, 2018 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intrexon Corporation ("Intrexon" ...

  • PR Newswirelast month

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON

    NEW YORK , Sept. 14, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (NYSE: XON).   Such investors ...

  • Business Wirelast month

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intrexon Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intrexon Corporation (“Intrexon” or “the Company”) (NYSE: XON) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Intrexon filed a Form 8-K with the SEC on August 9, 2018, announcement that the Company would restate its unaudited interim consolidated financial statements for the quarter ended March 31, 2018.

  • Business Wirelast month

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Intrexon Corporation – XON

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Intrexon Corporation resulting from allegations that Intrexon may have issued materially misleading business information to the investing public.

  • GlobeNewswirelast month

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Intrexon Corporation

    NEW YORK, Sept. 13, 2018-- Levi & Korsinsky announces it has commenced an investigation of Intrexon Corporation concerning possible violations of federal securities laws.. On August 9, 2018, Intrexon filed ...